Teva and Active Biotech not giving up on EU-spurned MS treatment

Carly Helfand

The EU's Committee for Medicinal Products for Human Use (CHMP) is sticking to its opinion to recommend against approval of and 's MS drug Nerventra. But the companies aren't up, announcing Friday that they remain committed to the clinical development program and plan to evaluate CHMP's feedback before they plot out their next steps.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS